GB0807605D0 - Lipid composition - Google Patents

Lipid composition

Info

Publication number
GB0807605D0
GB0807605D0 GBGB0807605.1A GB0807605A GB0807605D0 GB 0807605 D0 GB0807605 D0 GB 0807605D0 GB 0807605 A GB0807605 A GB 0807605A GB 0807605 D0 GB0807605 D0 GB 0807605D0
Authority
GB
United Kingdom
Prior art keywords
lipid composition
delivery
accordance
pharmaceutical compositions
circadian rhythm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0807605.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immedica UK Ltd
Original Assignee
Diurnal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diurnal Ltd filed Critical Diurnal Ltd
Priority to GBGB0807605.1A priority Critical patent/GB0807605D0/en
Publication of GB0807605D0 publication Critical patent/GB0807605D0/en
Priority to JP2011506766A priority patent/JP5727925B2/ja
Priority to PT97383822T priority patent/PT2273984E/pt
Priority to AU2009241910A priority patent/AU2009241910B2/en
Priority to DK09738382.2T priority patent/DK2273984T3/da
Priority to EP09738382.2A priority patent/EP2273984B1/en
Priority to PCT/GB2009/001068 priority patent/WO2009133352A2/en
Priority to CN2009801149913A priority patent/CN102083421B/zh
Priority to PL09738382T priority patent/PL2273984T3/pl
Priority to US12/989,948 priority patent/US9012436B2/en
Priority to ES09738382.2T priority patent/ES2502242T3/es
Priority to CA2722408A priority patent/CA2722408C/en
Priority to EP13186572.7A priority patent/EP2722038A3/en
Priority to KR1020107025087A priority patent/KR101617811B1/ko
Priority to IL208612A priority patent/IL208612A/en
Priority to ZA2010/07612A priority patent/ZA201007612B/en
Priority to IL236400A priority patent/IL236400A/en
Priority to US14/601,839 priority patent/US20150133417A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0807605.1A 2008-04-28 2008-04-28 Lipid composition Ceased GB0807605D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB0807605.1A GB0807605D0 (en) 2008-04-28 2008-04-28 Lipid composition
KR1020107025087A KR101617811B1 (ko) 2008-04-28 2009-04-27 지질조성
PL09738382T PL2273984T3 (pl) 2008-04-28 2009-04-27 Kompozycja lipidowa
ES09738382.2T ES2502242T3 (es) 2008-04-28 2009-04-27 Composición de lípidos
AU2009241910A AU2009241910B2 (en) 2008-04-28 2009-04-27 Lipid composition
DK09738382.2T DK2273984T3 (da) 2008-04-28 2009-04-27 Lipidsammensætning
EP09738382.2A EP2273984B1 (en) 2008-04-28 2009-04-27 Lipid composition
PCT/GB2009/001068 WO2009133352A2 (en) 2008-04-28 2009-04-27 Lipid composition
CN2009801149913A CN102083421B (zh) 2008-04-28 2009-04-27 脂质组合物
JP2011506766A JP5727925B2 (ja) 2008-04-28 2009-04-27 脂質組成物
US12/989,948 US9012436B2 (en) 2008-04-28 2009-04-27 Lipid composition
PT97383822T PT2273984E (pt) 2008-04-28 2009-04-27 Composição lipídica
CA2722408A CA2722408C (en) 2008-04-28 2009-04-27 Lipid composition for enhancing steroid solubility
EP13186572.7A EP2722038A3 (en) 2008-04-28 2009-04-27 Lipid Composition
IL208612A IL208612A (en) 2008-04-28 2010-10-11 A pharmaceutical composition containing natural testosterone and a lipid-based carrier
ZA2010/07612A ZA201007612B (en) 2008-04-28 2010-10-25 Lipid composition
IL236400A IL236400A (en) 2008-04-28 2014-12-22 A pharmaceutical composition containing natural testosterone and a lipid-based carrier
US14/601,839 US20150133417A1 (en) 2008-04-28 2015-01-21 Lipid composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0807605.1A GB0807605D0 (en) 2008-04-28 2008-04-28 Lipid composition

Publications (1)

Publication Number Publication Date
GB0807605D0 true GB0807605D0 (en) 2008-06-04

Family

ID=39522593

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0807605.1A Ceased GB0807605D0 (en) 2008-04-28 2008-04-28 Lipid composition

Country Status (15)

Country Link
US (2) US9012436B2 (https=)
EP (2) EP2722038A3 (https=)
JP (1) JP5727925B2 (https=)
KR (1) KR101617811B1 (https=)
CN (1) CN102083421B (https=)
AU (1) AU2009241910B2 (https=)
CA (1) CA2722408C (https=)
DK (1) DK2273984T3 (https=)
ES (1) ES2502242T3 (https=)
GB (1) GB0807605D0 (https=)
IL (2) IL208612A (https=)
PL (1) PL2273984T3 (https=)
PT (1) PT2273984E (https=)
WO (1) WO2009133352A2 (https=)
ZA (1) ZA201007612B (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
CA2604943C (en) 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
EP2257220B1 (en) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Multi-function, foot-activated controller for imaging system
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
KR102568894B1 (ko) * 2011-05-15 2023-08-21 에이세러스 바이오파마 인크. 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014096139A1 (en) 2012-12-20 2014-06-26 Solural Pharma ApS Solid oral dosage form of testosterone derivative
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
SG11201507288UA (en) 2013-03-15 2015-10-29 Mochida Pharm Co Ltd Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
KR101440726B1 (ko) * 2013-04-16 2014-09-18 중앙대학교 산학협력단 가용화제를 포함하는 림프계 약물전달 시스템용 조성물
EP3054940B1 (en) * 2013-10-07 2020-09-23 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
SG11201609352TA (en) 2014-06-19 2017-01-27 Solural Pharma ApS Solid oral dosage form of lipophilic compounds
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
KR102514657B1 (ko) * 2014-08-28 2023-03-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 테스토스테론의 제형 및 이를 이용한 치료 방법
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR101679380B1 (ko) * 2015-09-10 2016-11-25 주식회사 유유제약 두타스테리드를 포함하는 약학적 조성물 및 이를 포함하는 캡슐 제형
CN106562949A (zh) * 2015-10-10 2017-04-19 浙江旭晨医药科技有限公司 甘油三酯类化合物在制备治疗多囊卵巢综合征药物中的应用
CN109069518B (zh) * 2016-03-02 2022-10-11 得克萨斯州大学系统董事会 睾酮制剂以及用其治疗的方法
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
WO2019046582A1 (en) * 2017-08-30 2019-03-07 Antares Pharma, Inc. TESTOSTERONE ESTER TRIGLYCERIDE FORMULATIONS
US11311554B2 (en) 2018-04-04 2022-04-26 Slayback Pharma Llc Pharmaceutical compositions of testosterone
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
CN111803632B (zh) * 2019-04-09 2022-04-29 北京五和博澳药业股份有限公司 黄酮多酚类药物自乳化组合物、其制备方法、药物组合物及用途
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
US12514862B2 (en) 2020-02-05 2026-01-06 Neurocrine UK Limited Testosterone containing pharmaceutical composition
WO2024014958A2 (en) * 2022-07-15 2024-01-18 Seranovo Holding B.V. Lides formulation platform
WO2024014959A2 (en) * 2022-07-15 2024-01-18 Seranovo Holding B.V. Micelle-generating formulations with improved hydrophobicity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098802A (en) * 1975-02-18 1978-07-04 Akzona Incorporated Oral pharmaceutical preparation having androgenic activity
GB1567515A (en) 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
US6541025B1 (en) 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
US7138389B2 (en) * 2004-02-09 2006-11-21 University Of Washington Oral androgen therapy using modulators of testosterone bioavailability
CA2604943C (en) 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same

Also Published As

Publication number Publication date
EP2722038A2 (en) 2014-04-23
CN102083421A (zh) 2011-06-01
ZA201007612B (en) 2011-07-27
ES2502242T3 (es) 2014-10-03
JP5727925B2 (ja) 2015-06-03
KR20110007169A (ko) 2011-01-21
EP2722038A3 (en) 2014-06-18
IL236400A (en) 2016-06-30
US20110039814A1 (en) 2011-02-17
AU2009241910B2 (en) 2013-10-24
WO2009133352A2 (en) 2009-11-05
AU2009241910A1 (en) 2009-11-05
EP2273984A2 (en) 2011-01-19
CA2722408C (en) 2018-01-30
IL236400A0 (en) 2015-01-29
CN102083421B (zh) 2012-12-12
US9012436B2 (en) 2015-04-21
IL208612A (en) 2015-03-31
PL2273984T3 (pl) 2015-04-30
DK2273984T3 (da) 2014-08-25
IL208612A0 (en) 2010-12-30
WO2009133352A3 (en) 2010-10-28
JP2011519846A (ja) 2011-07-14
PT2273984E (pt) 2014-11-03
EP2273984B1 (en) 2014-07-30
CA2722408A1 (en) 2009-11-05
US20150133417A1 (en) 2015-05-14
KR101617811B1 (ko) 2016-05-03

Similar Documents

Publication Publication Date Title
GB0807605D0 (en) Lipid composition
IL275854A (en) Pharmaceutical composition and its administration
IL276157A (en) Pharmaceutical preparations and methods for transferring them related to them
IL206784A0 (en) Pharmaceutical compositions containing a phyto-cannabinoid in combination with an anti- psychotic medicine
ZA201100615B (en) Appetising medicament for oral administration in solid form
IL195764A0 (en) Compositions and methods for drug delivery
IL208708A0 (en) Carbidopa/lipodopa gastroretentive drug delivery
MY204500A (en) Dosing regimen associated with long acting injectable paliperidone esters
IL216374A0 (en) Compositions and methods for drug delivery
IL206835A0 (en) Methods and compositions for oral administration of insulin
ZA200903129B (en) Improvements in an relating to drive mechanisms suitable for use in drug delivery devices
PL2303369T3 (pl) Zespół napędowy odpowiedni do użytku w urządzeniu dostarczającym lek oraz urządzenie dostarczające lek
ZA201105486B (en) Aminotetraline derivatives,pharmaceutical compositions containing them,and their use in therapy
MY156913A (en) Oral administration of peripherally-acting opioid antagonists
EP2010162A4 (en) COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
AU319890S (en) Frame for oral appliance
EP2226071A4 (en) COMPOSITIONS FOR ORAL ADMINISTRATION
EP2370068A4 (en) METHOD AND COMPOSITIONS FOR DELIVERING MEDICAMENTS TO THE LUNG
IL211888A0 (en) Compositions and methods for achieving sustained therapeutic drug concentrations in a subject
EP2328511A4 (en) ACTIVE RELEASE IMPLANTS
AU322640S (en) Oral hygiene device
ZA201102405B (en) Pharmaceutical composition for oral administration
GB2456528B (en) Antioxidant for use in cosmetic, medicated and pharmaceutical compositions
AU2008900631A0 (en) Oral insulin composition and delivery
MX2009012458A (es) Forma de dosificacion oral que permite una rapida absorcion de un farmaco.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)